Q-omics provides the consensus-scored ZNF722P profile across patient tissues and cancer cell-line models. ZNF722P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ZNF722P is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, ZNF722P RNA expression shows 8,487 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, BRCA, and TGCT as cancer lineages where ZNF722P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF722P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF722P survival associations across molecular data types. ZNF722P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF722P RNA expression–survival associations across cancer types. High ZNF722P expression shows unfavorable associations in COAD, DLBC, KICH, KIRP, ESCA and PCPG. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for ZNF722P RNA expression.
This table summarizes ZNF722P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF722P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF722P shows higher tumor expression in BRCA, LIHC and LUAD. The BRCA box plot shows higher ZNF722P RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .033).
This table shows molecular features associated with ZNF722P in patient tissues and cancer cell lines. In patient samples, ZNF722P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
